secwatch.observer — SEC 8-K summary
======================================

Issuer:     EXELIXIS, INC. (EXEL)
CIK:        0000939767
Form:       8-K
Filed at:   2025-07-28T23:59:59+00:00
Accession:  0000939767-25-000111
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Exelixis Q2 2025: total rev $568M, GAAP EPS $0.65; CABOMETYX NET launch, positive STELLAR-303
--------------------------------------------------------------------------------

- Total revenues $568.3M; product revenues $520.0M (+19% YoY); collaboration rev $48.2M (down $151M due to prior-year Ipsen milestone).
- GAAP net income $184.8M ($0.65 diluted EPS); non-GAAP net income $212.6M ($0.75 diluted EPS).
- CABOMETYX launch in advanced NET capturing leading share, representing ~4% of Q2 CABOMETYX business.
- Positive topline results from zanzalintinib STELLAR-303 study in colorectal cancer; plan to file for approval.
- Early pipeline advancing: phase 1 trials for XL309, XB010, XB628; XB371 entering clinic.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/939767/000093976725000111/0000939767-25-000111-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/939767/000093976725000111/exel-20250728.htm
  HTML page:      https://secwatch.observer/filing/0000939767-25-000111

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer